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Abstract
Background: Genome wide microarray studies have the potential to unveil novel disease entities.
Clinically homogeneous groups of patients can have diverse gene expression profiles. The definition
of novel subclasses based on gene expression is a difficult problem not addressed systematically by
currently available software tools.
Results: We present a computational tool for semi-supervised molecular disease entity detection.
It automatically discovers molecular heterogeneities in phenotypically defined disease entities and
suggests alternative molecular sub-entities of clinical phenotypes. This is done using both gene
expression data and functional gene annotations.
We provide stam, a Bioconductor compliant software package for the statistical programming
environment R. We demonstrate that our tool detects gene expression patterns, which are
characteristic for only a subset of patients from an established disease entity. We call such
expression patterns molecular symptoms. Furthermore, stam finds novel sub-group stratifications
of patients according to the absence or presence of molecular symptoms.
Conclusion: Our software is easy to install and can be applied to a wide range of datasets. It
provides the potential to reveal so far indistinguishable patient sub-groups of clinical relevance.
Background
Microarray analysis is among the most promising clinical
applications of modern genomics. It opens perspectives
for more reliable and efficient diagnosis of established
tumor entities [1,2], risk group determination [3,4], and
the prediction of response to treatment [5]. In the super-
vised setting, various software tools implementing algo-
rithms from statistical learning theory are available and
have been evaluated in the context of microarray data (e.g.
[6-10]).
All these methods aim for reproducing or predicting pre-
defined clinical phenotypes. However, often clinical phe-
notypes will not be homogeneous from a molecular point
of view. For example, when distinguishing between recur-
rent and non-recurrent disease, it is of course possible that
recurrence has various molecular backgrounds. If this is
the case, one will expect different molecular changes in
different patients, and purely supervised analysis is
unsatisfactory.
In several studies, unsupervised clustering algorithms
have been applied to patient profiles, with the aim to
Published: 25 August 2005
BMC Bioinformatics 2005, 6:211 doi:10.1186/1471-2105-6-211
Received: 16 March 2005
Accepted: 25 August 2005
This article is available from: http://www.biomedcentral.com/1471-2105/6/211
© 2005 Lottaz and Spang; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Bioinformatics 2005, 6:211 http://www.biomedcentral.com/1471-2105/6/211define novel disease entities [11-14]. However, clustering
of patients is not straightforward, since the clinical rele-
vance of a clustering result is often unclear. It is quite pos-
sible that a given clustering reflects unimportant
covariates like gender and age or even experimental arti-
facts. This is usually avoided by visual inspection of the
clustered data and an educated manual selection of inter-
esting genes. Automated software tools for this problem
are not available so far.
We have recently suggested a novel algorithm for semi-
supervised analysis called structured analysis of microarrays
[15]. We consider the setting where a disease group is to
be distinguished from a set of patients with a different
clinical phenotype (controls). Instead of determining a
single global signature to detect all disease cases, we gen-
erate several local signatures, which identify only subsets.
We call the local signatures molecular symptoms. A special
feature of the method is that it produces multiple candi-
date symptoms and characterizes each by a functional
annotation, like patients with poor prognosis and altered
expression of apoptosis related genes. The functional
annotations stored in the Gene Ontology (GO) are used
to ensure biological focus.
In GO [16], terms describing biological processes, molec-
ular functions and cellular localizations are organized in a
directed acyclic graph, where each node represents a bio-
logical process and child-terms are either members or rep-
resentatives of their parent-terms. Genes are attributed to
nodes according to the knowledge the biological research
community has gathered so far. Molecular symptoms
found by stam exclusively contain genes associated with
one node of the Gene Ontology and therefore have a bio-
logical focus.
For each patient and each node classifier stam calculates a
value between 0 and 1 for each relevant molecular symp-
tom. These values indicate how likely it is that a patient
belongs to the disease class according to the correspond-
ing molecular symptom. In addition, we suggest to use
patterns of absence or presence of molecular symptoms to
stratify patients into subclasses. An overview of the algo-
rithm is given in Figure 1.
Implementation
A detailed description of structured analysis of microar-
rays is given in [15]. Here we only give a brief review of the
method.
We use Gene Ontology's hierarchical structure. Based on
the GO graph of biological terms, stam generates a classi-
fier graph holding one classifier for each node. The classi-
fiers only depend on genes annotated to corresponding
nodes or their descendants. In a nutshell, stam consists of
the following steps as illustrated in Figure 2:
• generate a rooted, directed classifier graph according to
the gene Ontology,
• construct leaf-node classifiers based on expression val-
ues of genes, which are directly annotated to the leaf
nodes,
• propagate the results through inner nodes to the root,
• and shrink the classifier graph to determine a concise set
of molecular symptoms.
We have implemented the algorithm based on the R pack-
age for statistical computing [17]. Time-consuming parts
of the method are written in C to improve computational
performance. Furthermore, we rely on packages from the
Bioconductor suite of bioinformatics tools [18].
The raw classifier graph
Starting from a node of interest specified by the user, stam
generates a graph of classifiers according to the structure
of the Gene Ontology. The graph is generated anew for
each chip type. Any GO node can be chosen to start the
procedure with this node as root of the graph. The default
is the root of the biological process branch of the gene
ontology. Our implementation uses Bioconductor meta-
data packages to obtain chip-specific associations of
probe-sets with genes as well as the generic GO structure.
Table 1 summarizes the annotation data, which is cur-
rently available for Affymetrix-GeneChip® microarrays.
Overview on structured analysis of microarraysFigure 1
Overview on structured analysis of microarrays. Input 
of stam is a gene expression dataset, the structure of the 
Gene Ontology and associations of genes with GO terms. 
The output of the method is a resolved diagnosis per patient 
according to molecular symptoms, arid thus a molecular 
stratification of patients according to absence and presence 
of these symptoms.
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Each leaf node contains a set of associated genes. The clas-
sifiers for leaf nodes are constructed using only these
genes. For each patient, it returns a number between zero
and one. Zero indicates clear evidence for the control
group, one indicates clear evidence for the disease group
and intermediate values represent levels of uncertainty. In
the current implementation we use the shrunken centroid
classifiers [9] implemented in the Bioconductor package
pamr for leaf node predictions.
Propagation of classifier results
For propagating leaf node results to inner nodes, weighted
sums of child classifications are used. Children with good
classification performance receive more weight than those
with poor performance. Thereby, stam measures perform-
ance according to the desired properties of molecular
symptoms by punishing low specificity more severely
than lack of sensitivity. Prediction results are propagated
from the leaf nodes towards the root in a postorder traver-
sal of inner nodes. Hence, stam always computes results
for all children before it computes results for the parent
stam's algorithm in a nutshellFigure 2
stam's algorithm in a nutshell. The algorithm for structured analysis of microarrays splits into three phases: classification in 
leaf nodes, propagation through inner nodes and shrinkage of the classifier graph. Calibration by the user allows for fine-tuning 
of specificity versus sensitivity in classifier evaluation and redundancy versus performance tradeoff in graph shrinkage.
Table 1: Gene Ontology annotations available in Bioconductor – For the microarrays listed in this table, Bioconductor meta data 
packages are available. The second column gives the number of leaf nodes the third column the number of inner nodes considered 
when generating classifier graphs. The last column reports the ratio of probe-sets being associated with any leaf node.
Species Probe-sets Leaf nodes Inner nodes Annotated
hgu133a human 22283 1649 1049 67.6%
hgu133b human 22645 1136 783 30.7%
hgul33plus2 human 54675 1725 1094 44.1%
hu6800 human 7129 1300 872 84.7%
hgu95av2 human 12625 1492 966 76.2%
hgu95b human 12620 972 669 33.3%
hgu95c human 12646 895 633 27.7%
hgu95d human 12644 866 603 22.9%
hgu95e human 12639 935 641 32.1%
mgu74av2 mouse 12488 1379 934 63.5%
mgu74bv2 mouse 12411 975 696 33.7%
mgu74cv2 mouse 11934 826 590 26.0%
moe430a mouse 22690 1538 1017 61.4%
moe430b mouse 22575 997 719 21.0%
rgu34a rat 8799 974 689 46.0%
rgu34b rat 8791 403 332 7.7%
rgu34c rat 8789 439 345 8.5%
rae230a rat 15866 1032 718 23.5%
rae230b rat 15276 319 297 3.1%
yg98 yeast 6777 1028 667 80.8%
YEAST yeast 5799 1030 668 99.9%
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BMC Bioinformatics 2005, 6:211 http://www.biomedcentral.com/1471-2105/6/211node. The root naturally displays an overall classification
result.
Classifier graph shrinkage
Many biological processes are not involved with the inves-
tigated phenotype. Therefore, stam simplifies the classifier
graph by eliminating irrelevant branches. This is done in
analogy to gene shrinkage in the shrunken centroid algo-
rithm [9]. stam controls the shrinkage process by calibrat-
ing a shrinkage parameter in a cross validation setting. We
define an objective function considering two independent
goals: good predictive performance in the root and a set of
molecular symptoms for patient stratification. For the sec-
ond goal aggressive shrinkage is counterproductive, since
it eliminates too many inherently heterogeneous molecu-
lar symptoms.
The program's output is a classifier graph, where each
node represents a molecular symptom. We have shown in
[15] that the collection of these classifiers yields state-of-
the-art predictive performance and allows for a resolved
diagnosis. A stam-diagnosis is more resolved than the
classification provided for training because molecular
symptoms are usually absent in some of the disease
patients. Patterns of absence and presence of molecular
symptoms identify smaller groups of patients and thus
provide an additional molecular stratification of patients.
Due to this unsupervised aspect within our supervised
method, we call our approach semi-supervised.
Results
Installing stam works like any other Bioconductor pack-
age either by downloading and installing from a local
copy or directly through the internet. We provide pack-
aged versions ready for download on the Bioconductor
web site [19] as well as on our own web page [20].
Computing with stam is done on a command-line level.
Gene expression matrices can either be provided as plain
R matrices or as exprSet Bioconductor objects. R can read
tab-delimited files written by any other software. stam
provides functions for cross validation, model fit, and pre-
diction. First, cross validation is applied on training data
to find the appropriate shrinkage level. The second func-
tion computes a classifier model given this shrinkage
level. This model can than be used by the prediction func-
tion to diagnose new patients and assign them to novel
molecular disease entities. For convenience all three steps
can be performed by one call of an evaluation function.
This function can also randomly split patients into a train-
ing and a test set.
For further illustration, we use a data set from a microar-
ray study on lung cancer [1]. The investigators have ana-
lyzed gene expression profiles from 186 lung cancer as
well as 17 non-tumor lung biopsies using hierarchical and
probabilistic clustering with the goal to uncover novel
molecular lung cancer entities. The study uses the HG-
U95Av2 microarray from Affymetrix and contains sam-
ples from various subtypes of lung cancer. For illustration,
we apply stam with the squamous cancers forming the
disease group of interest and all other cancers as controls.
Cross validation evaluationFigure 3
Cross validation evaluation. For several graph shrinkage candidates error rates in the root node, the root performance and 
the mean redundancy (top panel), as well as the number of nodes remaining in the shrunken graph and the number of genes 
accessible through these (bottom panel) are shown for the task to identify squamous lung cancers. The vertical lines show the 
automatically chosen shrinkage level.
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BMC Bioinformatics 2005, 6:211 http://www.biomedcentral.com/1471-2105/6/211Nodewise evaluationFigure 4
Nodewise evaluation. Classifiers for all nodes representing molecular symptoms have different performance. The left panels 
oppose performance to redundancy (to all other nodes remaining in the shrunken classifier graph). The right panels contrast 
sensitivity to specificity. The upper panels are drawn using training data while the lower ones are generated based on the test 
data.
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BMC Bioinformatics 2005, 6:211 http://www.biomedcentral.com/1471-2105/6/211In the dataset there are 21 squamous carcinomas. The 203
samples are randomly split into a training set (135 sam-
ples containing 14 squamous) and a test set (68 samples
containing 7 squamous).
Automatic and manual calibration of graph shrinkage
Graph shrinkage can be calibrated automatically by cross
validation or manually. To this end, stam provides two
performance scores and corresponding plots. The first
score is root performance measured as what would be the
log-likelihood in a probabilistic setting. The second score,
called mean redundancy, represents the diversity of
molecular symptoms in the graph. It is the mean of pair-
wise redundancies. Here as well we interpret classifier out-
puts as probabilities. Our definition of pairwise
redundancy is then the negative logarithm of the proba-
bility for unequal class prediction, stam aims for small
values for both scores. While automated optimization
uses an affine combination of the scores as objective func-
tion [15], manual calibration allows for a problem spe-
cific adjustment of the performance versus diversity trade
off. The left pane of Figure 3 displays both scores for the
whole classifier graph together with the error rate in the
root node depending on the graph shrinkage level. The
right pane of Figure 3 shows the number of nodes in the
graph, and the number of genes accessible through these
Shrunken classifier graphFig re 5
Shrunken classifier graph. For the squamous lung cancer identification this classifier graph containing 90 nodes is generated. 
Its 24 leaf nodes use 1614 probes (12.8% of all probes on the HG-U95Av2 microarray).
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BMC Bioinformatics 2005, 6:211 http://www.biomedcentral.com/1471-2105/6/211nodes. Figure 4 resolves the scores node per node. It con-
tains scatter plots displaying sensitivity versus specificity
and redundancy versus performance of single nodes. The
redundancy of single nodes is defined in [15]. It is high if
the corresponding classifier provides results which are
similar to those of other classifiers in the shrunken graph.
Browsable results
Results are written on interlinked HTML pages. Links
allow navigation along the edges of the classifier graph.
The pages contain classification results and performance
evaluation for all nodes as well as overall information on
cross-validation, model fit and root diagnosis of patients.
Molecular symptoms imageFigure 6
Molecular symptoms image. Resolved diagnoses for all squamous lung cancers are represented by the columns in this 
image. Rows represent molecular symptoms. The seven samples from the test set are marked with capital letters on the x-axis. 
Only a few samples including the test sample E present all molecular symptoms. Several samples lack some of the molecular 
symptoms. For instance, the symptom attributed to "intra-cellular protein transport" is not present in some of the training 
samples as well as samples B, C, F and G from the test set.
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BMC Bioinformatics 2005, 6:211 http://www.biomedcentral.com/1471-2105/6/211For inner nodes the propagation weights are provided and
for leaf nodes the genes used for classification can be dis-
played. The user can further explore term definitions and
probe-set annotations through external links to the Gene
Ontology and the Affymetrix web sites.
If the package graphviz [21] is installed, an interactive
graphical representation of the classifier graph is included.
Links on the nodes lead to the corresponding node-spe-
cific result page. Figure 5 shows an example using the lung
cancers dataset.
For visualizing patient stratification a molecular symp-
toms image is generated, as illustrated in Figure 6. Classi-
fier outputs are color coded with bright colors
representing presence, and dark color absence of a molec-
ular symptom. Columns represent patients, and rows
molecular symptoms. Rows and columns are arranged
such that similar rows and columns are placed together.
Interactive use of stam
For the interactive exploration of the graph shrinkage level
and other parameters affecting visual output, we have
implemented a WWW based solution. stam can write
HTML forms for these parameters directly on the HTML
result pages. We provide CGI scripts with the package,
which collect the user's entries and pass them to the stam
server. This server is also included in the R package. It con-
sists of an R function which, is constantly polling for user
requests submitted via the internet. The architecture is
illustrated in Figure 7. The user's WWW browser is redi-
rected to a progress page which reloads automatically
every second. As soon as the stam server has finished treat-
ing the request, the browser is redirected to an updated
result page.
Discussion
In this paper we present a software package to integrate
biological annotation into statistical class prediction anal-
ysis of microarray data in an a priori fashion. We use the
functional annotation collected in the Gene Ontology
database to construct structured classifiers. Class predic-
tions are computed for each term in the Gene Ontology
which is related to the disease. Our method allows for bio-
logically resolved diagnosis of patients. It is thus able to
stratify complex clinical phenotypes, where different
patients who show the phenotype may display different
molecular characteristics.
We suggest structured analysis of microarrays for different
applications. In addition to predictive performance we
also aim for making underlying disease mechanisms
transparent. We do this by identifying molecular symp-
toms associated to subsets of patients in the disease group.
Molecular symptoms are always restricted to well defined
biological processes. Patients who are positive for a
molecular symptom display specific gene expression in
the corresponding process. Not all patients in the disease
group are positive for every identified molecular symp-
tom, but some patients can be positive for more than one
of them. Using patterns of absence and presence of molec-
ular symptoms, we define an additional molecular strati-
fication of patients.
Conclusion
In summary, stam is a novel algorithm for uncovering pre-
viously unknown molecular disease sub-entities. The R
package is easily accessible to all researchers working with
Affymetrix® oligo chips.
Availability and requirements
The Bioconductor compliant R package stam is available
through the Bioconductor web site [19]. Alternatively we
also make it available on the Computational Diagnostics
Software Page at the Max Planck Institute for Molecular
Genetics in Berlin [20]. There, the source package is avail-
able for download and we also run a Bioconductor com-
pliant package repository.
Our software is written for the R package for statistical
computing downloadable from [22]. An installation of
version 2.0.0 or later of the R software is needed to run
stam. Our software is based on other Bioconductor pack-
ages, namely the meta data packages for the Gene Ontol-
ogy annotations. We recommend to install release 1.5 of
Client-server architecture for interactive explorationFigure 7
Client-server architecture for interactive explora-
tion. Architecture of stam's server feature. CGI scripts 
deposit requests in a task repository from where the stam-
server reads and executes them.
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the Bioconductor suite from [19]. For the layout of classi-
fier graphs, we rely on the graphviz package versions 1.10
or later available at [23].
We have extensively used stam on Linux installations on
i686 based machines as well as alpha based UNIX
machines running OSF1 and True64 operating systems.
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